All News

A target trial emulation found GLP-1 RA initiation was associated with a 21% lower 3-year fragility fracture risk compared with DPP-4 inhibitor therapy.

Shahzad Mian, MD, explains dry eye disease symptoms, key risk factors, and practical management strategies like drops and warm compresses.

This eta-analysis shows sleep variability—not averages—signals psychosis risk, with stage-specific patterns to guide digital biomarkers and care.

Agentic AI can fix behavioral health referral overload by matching patients to the right providers and boosting follow-through, cutting early dropout.

A recent study found semaglutide more than doubled the likelihood of MASH resolution, but it did not significantly improve fibrosis.

A new review argues that bulevirtide is unlikely to succeed as a stand-alone treatment and calls for combination regimens that restore antiviral immunity.

A budget impact model projects that covering delgocitinib cream for moderate to severe CHE could save a hypothetical US health plan $87.8 million over 3 years.

Moving to a subQ formulation makes sense, if you want to be 100% convenient for patients and the centers that treat them, explains Xavier Leleu, MD, PhD.

A new analysis finds up to a 98.8% probability that liberal transfusion lowers 30-day death or myocardial infarction risk vs restrictive care.

New cancer drugs reached patients fastest, but overall access timelines remained lengthy across the US, France, Germany, and Switzerland.

East Asian patients with generalized myasthenia gravis (gMG) saw meaningful nipocalimab benefits in a Vivacity-MG3 subgroup analysis.

A dermatology review proposes sorting patients with overlapping atopic dermatitis and alopecia areata into 3 immunophenotype-guided archetypes to select and sequence systemic therapy.

CMS value-based payment models underrepresent Black, Hispanic, dual-eligible, and disadvantaged Medicare beneficiaries compared with the broader population.

Clinicians say workflow changes, not education alone, are closing screening and treatment gaps in cardio-kidney-metabolic (CKM) care.

These results provide support for a potential new standard of care in the relapsed/refractory setting.

Doug Francis of Rhythm Healthcare on what's driving respiratory and mobility care out of facilities and into patients' homes

June delivered 5 FDA firsts; FDA panel weighs peptide access; dermatology absorbs PA costs; Trump sets tariff timeline; digital QI trims LDL-C.

The autoinjector delivers subcutaneous furosemide with IV-equivalent exposure in under 10 seconds for adults with heart failure or CKD-related edema.

June 2026 brought 5 FDA firsts across infectious disease, oncology, and rare disease, expanding treatment options and addressing unmet patient needs.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Clesrovimab remained well tolerated through a second RSV season in infants at increased risk of severe RSV.

The Pharmacy Compounding Advisory Committee meets July 23-24 to discuss whether pharmacies may dispense BPC-157, TB-500, and 5 other peptides.

Dermatologists spend 13 hours weekly on prior authorization as health plans tout an 11% reduction in requests.

Eplontersen added to standard of care did not significantly reduce cardiovascular death and recurrent events, a study finds.

Trump said imported generic drugs will face no tariff for 2 years starting August 1, then a 100% rate in 2028 and 200% in 2029, extending his trade fight to the drugs most Americans actually take.

New York City health officials confirmed a 5th fatality in the Upper East Side Legionnaires' disease outbreak.

This research reinforces that fixed-duration, chemotherapy-free regimens can offer both a tolerability and a patient-experience advantage over CIT.

FDA approves zidesamtinib for ROS1-positive NSCLC after prior TKIs, offering a new option for resistant and CNS-active disease.